Chalmers, Iain

Djulbegovic, Benjamin

Glasziou, Paul

Ioannidis, John P A

Klocksieben, Farina A

Mhaskar, Rahul

Reljic, Tea

VanDenBergh, Magali

English

Benjamin Djulbegovic

Paul Glasziou

Farina A. Klocksieben

Tea Reljic

Magali VanDenBergh

Rahul Mhaskar

John P.A. Ioannidis

Iain Chalmers

Crossref

Journal of Clinical Epidemiology

Larger effect sizes in nonrandomized studies are associated with higher rates of EMA licensing approval

OBJECTIVES: Evaluate how often the European Medicines Agency (EMA) has authorized drugs based on non-randomized studies and whether there is an association between treatment effects and EMA preference for further testing in RCTs.STUDY DESIGN AND SETTING: We reviewed all initial marketing authorizations in the EMA database on human medicines between 1995 and 2015 and included authorizations granted without randomized data. We extracted data on treatment effects and EMA preference for further testing in RCTs.RESULTS: Of 723 drugs, 51 were authorized based on non-randomized data. These 51 drugs were licensed for 71 indications. In the 51 drug-indication pairs with no preference for further RCT testing, effect estimates were large [OR 12.0 (95% CI: 8.1 to 17.9)] compared to effect estimates in the 20 drug-indication pairs for which future RCTs were preferred [OR 4.3 (95%CI 2.8 to 6.6)], with a significant difference between effects (p=0.0005).CONCLUSIONS: Non-randomized data were used for 7% of EMA drug approvals. Larger effect sizes were associated with greater likelihood of approval based on non-randomized data alone. We did not find a clear treatment effect threshold for drug approval without RCT evidence.</p

Bond University Research Portal

https://pure.bond.edu.au/ws/files/27049025/Larger_effect_sizes_in_non_randomized_studies_are_associated_with_higher_rates_of.pdf

Larger effect sizes in nonrandomized studies are associated with higher rates of EMA licensing approval

Abstract

Similar works

Full text

Available Versions

Crossref

Bond University Research Portal